Fundamental Analysis of Merck & Company Inc - Growth / Value Index
MRK - Valuation Highlights
Valuation Analysis
Tsr Value Index - Good Score of 67.19
Undervalued - Price to Intrinsic Value of 0.198
Price to Earning Ratio is 12.31 and EV to EBITDA is 9.79 suggesting company is undervalued.
Book Value in last 3 years is trending up
Valuation Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Price to Earning | 12.31 | 13.79 | -97.87 % | |
| Price to Book | 3.43 | 1.94 | -69.18 % | 5.63 |
| Price to Sales | 3.65 | 3.68 | -6.54 % | |
| Enterprise Value to EBITDA Multiple | 9.79 | 9.65 | -76.26 % |
MRK - Profitability Highlights
Profitability Analysis
Tsr Profitability Index - Excellent Score of 85.00
Piotroski F Score - Excellent Value of 8.0
Earning Yield of 8.13 %
Excellent QoQ /QoQ FY EPS growth
Company Earning excess return
During the past twelve months, the company has given a strong Return On Equity of 39.95%
During the past twelve months, the company has given a strong Net Margin of 29.63%
All key Trailing Twelve Months Margin growing by 15 %
Reasonable Dividend Yield of 3.69 %
Annual Net Profit in last 3 years is trending up
Company's Net Profit is increasing for last 5 Quarters
Company's Profit Before Tax is increasing for last 5 Quarters
EBITDA is continuously increasing for last 3 Years
Steady Growth in EPS for last four quarters
Good Return On Capital Employed of 20.54
Profitability Key Ratios
| Ratio | TTM | Latest FY | Yoy Change | MRQ |
|---|---|---|---|---|
| Return On Equity | 39.95 | 38.41 | 3855.10 % | 11.16 |
| Return On Asset | 17.36 | 22.15 | 6373.12 % | 5.20 |
| Net Profit Margin | 29.63 | 26.68 | 4293.38 % | 33.49 |
| Operating Profit Margin | 39.41 | 35.36 | 619.66 % | 43.74 |
| EBITDA Margin | 40.46 | 41.98 | 265.40 % | 39.04 |
Highlights
| Market Cap | 230629 M |
| Enterprise Value | 254498 M |
| Price/Book TTM | 3.43 |
| Outstanding Share | 2482.02 M |
| Float/ Outstanding Share | 99.84% |
| Dividend Yield | 3.50 % |
Share Holding
Guru Numbers
| Price/Graham No | 1.03 |
| Peter Lynch Ratio | 373.86 |
| Piotroski F Score | 8.00 |
| Altman Z Score | -0.0135 |
| Sloan Ratio | 0.0438 |
| Peter Lynch Fair Value | 82.14 |
MRK - Growth Highlights
Growth Analysis
YoY Net Margin Jump by 4293.38%
Annual sales of the company is increased for three years in a row
Tsr Growth Index - Poor Score of 28.05
Company's Total Assets is Decreasing for last 3 years
Growth Key Fields
| Field | TTM | YoY Growth | QoQ Growth |
|---|---|---|---|
| Revenue | 64235.00 M | 6.74 % | 9.30 % |
| Gross Profit | 53211.00 M | 17.94 % | 15.54 % |
| EBITDA | 25987.67 M | 290.03 % | 34.93 % |
| Net Profit | 19034.00 M | 4589.59 % | 30.68 % |
| EPS | 7.55 | 4600.66 % | NA |
MRK - Stability Highlights
Stability Analysis
Altman Z Score of -0.0138 suggest high risk
Stability Key Ratios
| Ratio | Latest FY | Yoy Change | MRQ |
|---|---|---|---|
| Debt to Equity Ratio | 0.833 | -11.44 % | 0.798 |
| Cash Ratio | 0.513 | 50.38 % | |
| Quick Ratio | 0.299 | -70.28 % | 1.44 |
| Shareholders Equity | 57.66 | 63.66 % | |
| Debt to EBITDA | 1.38 | -73.08 % |
Historical Valuation Ratios of Merck & Company Inc
Historical Valuation Ratios
Loading ...
Historical Profitability Ratios of Merck & Company Inc
Historical Profitability Ratios
Loading ...
Historical Efficiency Ratios of Merck & Company Inc
Historical Efficiency Ratios
Loading ...
Historical Solvency Ratios of Merck & Company Inc
Historical Solvency Ratios
Loading ...
Note : All Data Generated at the End of Trading Hours (EOD Data)






